8 research outputs found

    Removal of luminal content protects the small intestine during hemorrhagic shock but is not sufficient to prevent lung injury.

    Get PDF
    The small intestine plays a key role in the pathogenesis of multiple organ failure following circulatory shock. Current results show that reduced perfusion of the small intestine compromises the mucosal epithelial barrier, and the intestinal contents (including pancreatic digestive enzymes and partially digested food) can enter the intestinal wall and transport through the circulation or mesenteric lymph to other organs such as the lung. The extent to which the luminal contents of the small intestine mediate tissue damage in the intestine and lung is poorly understood in shock. Therefore, rats were assigned to three groups: No-hemorrhagic shock (HS) control and HS with or without a flushed intestine. HS was induced by reducing the mean arterial pressure (30 mmHg; 90 min) followed by return of shed blood and observation (3 h). The small intestine and lung were analyzed for hemorrhage, neutrophil accumulation, and cellular membrane protein degradation. After HS, animals with luminal contents had increased neutrophil accumulation, bleeding, and destruction of E-cadherin in the intestine. Serine protease activity was elevated in mesenteric lymph fluid collected from a separate group of animals subjected to intestinal ischemia/reperfusion. Serine protease activity was elevated in the plasma after HS but was detected in lungs only in animals with nonflushed lumens. Despite removal of the luminal contents, lung injury occurred in both groups as determined by elevated neutrophil accumulation, permeability, and lung protein destruction. In conclusion, luminal contents significantly increase intestinal damage during experimental HS, suggesting transport of luminal contents across the intestinal wall should be minimized

    Detection of proteases in whole blood and other biological fluids in different diseases

    No full text
    Proteases are enzymes that cleave proteins by hydrolyzing their peptide bonds. The level of proteases have been shown to be elevated in many diseases including shock, diabetes, several types of cancers, and coagulation disorders. Thus the ability to measure protease activity directly in whole blood, and other complex samples will allow for better diagnostics, better understanding of the disease progression, and the development of better therapeutics. Current techniques used to measure protease activity required considerable amounts of sample preparation, which is 1) time-consuming 2) costly and 3) alters the sample, making the reads less accurate. In this dissertation we have further developed a novel assay, which allows rapid measurements of different proteases activities directly in whole blood, and other complex samples, requiring no sample preparation. The technology used by the charge-changing fluorescent substrates assays consists of a simple electrophoretic format. In the past proteases have not been fully studied in many conditions, because sample preparation lead to un-accurate measurements of the proteases in most cases. In this dissertation we present the measurement of protease activity in the lymph fluid of rats, after physiological shock. An elevation of the metalloproteases-2, and -9, trypsin, and chymotrypsin activity after shock was observed. We also were able to measure the protease activity in whole blood samples of type 2 diabetics during a meal; where we found an elevation of metalloproteases -2, and -9, and elastase activity. Metalloproteases-2, and -9 activities were measured in whole untreated blood samples of CLL patients, where they were elevated, and it was observed that this activity came from B-cells. Because of the simple format of our assay, we have design and tested a prototype for a point of care system, which detected thrombin activity in whole untreated blood in only 27- minutes. We have then demonstrated, that our charge- changing fluorescent substrate assay can be used with real complex clinical samples and no sample preparation for the detection of protease activities to : 1) gain a better understanding of the disease progression, 2) develop better diagnostics, and 3) develop new therapeutics for the different diseases, which will ultimately help patients managing their condition

    Efficacy of a Metalloproteinase Inhibitor in Spinal Cord Injured Dogs

    Get PDF
    <div><p>Matrix metalloproteinase-9 is elevated within the acutely injured murine spinal cord and blockade of this early proteolytic activity with GM6001, a broad-spectrum matrix metalloproteinase inhibitor, results in improved recovery after spinal cord injury. As matrix metalloproteinase-9 is likewise acutely elevated in dogs with naturally occurring spinal cord injuries, we evaluated efficacy of GM6001 solubilized in dimethyl sulfoxide in this second species. Safety and pharmacokinetic studies were conducted in naïve dogs. After confirming safety, subsequent pharmacokinetic analyses demonstrated that a 100 mg/kg subcutaneous dose of GM6001 resulted in plasma concentrations that peaked shortly after administration and were sustained for at least 4 days at levels that produced robust <i>in vitro</i> inhibition of matrix metalloproteinase-9. A randomized, blinded, placebo-controlled study was then conducted to assess efficacy of GM6001 given within 48 hours of spinal cord injury. Dogs were enrolled in 3 groups: GM6001 dissolved in dimethyl sulfoxide (n = 35), dimethyl sulfoxide (n = 37), or saline (n = 41). Matrix metalloproteinase activity was increased in the serum of injured dogs and GM6001 reduced this serum protease activity compared to the other two groups. To assess recovery, dogs were <i>a priori</i> stratified into a severely injured group and a mild-to-moderate injured group, using a Modified Frankel Scale. The Texas Spinal Cord Injury Score was then used to assess long-term motor/sensory function. In dogs with severe spinal cord injuries, those treated with saline had a mean motor score of 2 (95% CI 0–4.0) that was significantly (P<0.05; generalized linear model) less than the estimated mean motor score for dogs receiving dimethyl sulfoxide (mean, 5; 95% CI 2.0–8.0) or GM6001 (mean, 5; 95% CI 2.0–8.0). As there was no independent effect of GM6001, we attribute improved neurological outcomes to dimethyl sulfoxide, a pleotropic agent that may target diverse secondary pathogenic events that emerge in the acutely injured cord.</p></div
    corecore